期刊文献+

阿立哌唑与利培酮治疗精神分裂症的对照研究 被引量:2

下载PDF
导出
摘要 目的比较阿立哌唑与利培酮治疗精神分裂症的疗效与安全性。方法将80例精神分裂症患者随机分为两组,每组各40例,分别给予阿立哌唑和利培酮治疗,疗程8w,采用阳性与阴性症状量表(PANSS),临床疗效总评量表(CGI—SI)、采用不良反应量表(TESS)评定疗效和不良反应。结果两组PANSS总分及CGI—Si评分均治疗前显著下降(P〈0.01),阿立哌唑组显效率78%,利培酮组显效率75%,两组疗效相仿(P〉0.05).阿立哌唑组的嗜睡、体重增加的不良反应明显低于利培酮组(P〈0.01),锥体外系反应、失眠、兴奋或激越与利培酮组相当,差异无显著性(P〉0.05)。结论阿立哌唑组与利培酮组治疗精神分裂症的疗效相当。阿立哌唑组的不良反应较利培酮组少而轻,阿利哌唑的安全性高,依从性好。
作者 李洪涛 马迅
出处 《医学信息》 2012年第8期148-148,共1页 Journal of Medical Information
  • 相关文献

参考文献3

  • 1黄文武,姜德国.抗精神病新药阿立哌唑[J].上海精神医学,2003,15(5):307-308. 被引量:153
  • 2Kern RS,Green MF,cornblatt BA,al.The neurocognitive effects of aripiprazole: an open-label comparison with olanzapin [J].Psycopharmacology,2006,187:312- 320.
  • 3Goodnick PJ,Jerry JM.Aripirazole:profile on efficacy and safety [J].Expert Opinion on Pharmacotherapy,2002,3(12):1773-1781.

二级参考文献15

  • 1[1]Kikuchi T, Tottori K, Uwahodo Y, et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl] butyloxy)-3,4-dihydro-2 ( 1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther, 1995 Jul, 274( 1 ) :329 ~ 336
  • 2[2]Fleishhacker WW. New developments in the pharmacotherapy of schizophrenia. J Neural transm Suppl, 2003, 105 ~ 117
  • 3[3]Oshiro Y, Sato S, Kurahashi N, et al. Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[ 4-( 4-phenyl-1-piperazinyl ) butoxy ]-3, 4-dthydro-2 (1H)-quinolinone derivatives. J Med Chem, 1998 Feb, 41 : 658 ~667
  • 4[4]Matsubayashi H, Amano T, Sasa M. Inhibition by aripiprazole of dopaminergic inputs to striatal neurons from substantia nigra. Psychopharmacolgy (Berl), 1999 Sep, 146(2) : 139 ~ 143
  • 5[5]Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropschopharmacolgy, 1999 Jun, 20(6) : 612~627
  • 6[6]Inoue A, Seto M, Sugita S, et al. differential effects on D2 dopamine receptor and prolactin gene expression by haloperidol and aripiprazole in the rat ptiuitary. Brain Res Mol Brain Res, 1998 apr, 55 : 285 ~292
  • 7[7]Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.Neuropsychopharmacology, 2003 May
  • 8[8]Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT ( 1 A) receptor. Eur J Pharmacol, 2002 Apr 26,441(3) : 137 ~140
  • 9[9]Goodnick P J, Jerry JM. aripiprazole: profile on efficacy and safety.Expert Opin Pharmacother, 2002 Dec, 3(12) : 1773 ~ 1781
  • 10[10]Stahl SM. dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors. J Clin Psychiatry, 2001 Nov, 62 (11 ) : 841 ~ 842

共引文献152

同被引文献11

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部